Accéder au contenu
Merck

Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry.

The American journal of surgical pathology (2013-06-14)
David J Dabbs, Stuart J Schnitt, Felipe C Geyer, Britta Weigelt, Frederick L Baehner, Thomas Decker, Vincenzo Eusebi, Stephen B Fox, Shu Ichihara, Sunil R Lakhani, Jose Palacios, Emad Rakha, Andrea L Richardson, Fernando C Schmitt, Puay-Hoon Tan, Gary M Tse, Anne Vincent-Salomon, Ian O Ellis, Sunil Badve, Jorge S Reis-Filho
RÉSUMÉ

Lobular neoplasia (LN) is a term that encompasses both lobular carcinoma in situ and atypical lobular hyperplasia. These lesions have been shown to constitute both risk indicators and nonobligate precursors of invasive breast cancer, they are relatively uncommon, and are most often identified in specimens taken for other reasons. Their incidence has increased in the last 2 decades, and novel variants, including a pleomorphic type, have been described. Loss of E-cadherin expression is recognized as a hallmark diagnostic feature of LN and invasive lobular carcinomas, and immunohistochemical (IHC) analysis using anti-E-cadherin antibodies has been proven to be a useful method to differentiate between lobular and ductal lesions. The frequent use of E-cadherin IHC analysis in routine diagnostic histopathology, however, has resulted in confusion with regard to the actual value of IHC with antibodies against E-cadherin and other proteins of the cadherin-catenin complex. This review provides an update on recent clinicopathologic and molecular data on LN and invasive lobular carcinoma and a discussion about the use and limitations of IHC with E-cadherin in diagnostic breast pathology.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
p53 (EP9) Rabbit Monoclonal Primary Antibody